You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

DEPINAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Depinar patents expire, and when can generic versions of Depinar launch?

Depinar is a drug marketed by Armour Pharm and is included in one NDA.

The generic ingredient in DEPINAR is cyanocobalamin; tannic acid; zinc acetate. There are nine drug master file entries for this compound. Additional details are available on the cyanocobalamin; tannic acid; zinc acetate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DEPINAR?
  • What are the global sales for DEPINAR?
  • What is Average Wholesale Price for DEPINAR?
Summary for DEPINAR
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 32
DailyMed Link:DEPINAR at DailyMed
Drug patent expirations by year for DEPINAR

US Patents and Regulatory Information for DEPINAR

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Armour Pharm DEPINAR cyanocobalamin; tannic acid; zinc acetate INJECTABLE;INJECTION 011208-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 1 of 1 entries

DEPINAR Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Pharmaceutical Drug Delivery: A Comprehensive Overview

Introduction to Pharmaceutical Drug Delivery

The pharmaceutical drug delivery market is on the cusp of significant growth, driven by several key factors. Understanding these dynamics is crucial for businesses and investors looking to navigate this complex and evolving industry.

Market Growth Outlook

The global pharmaceutical drug delivery market is projected to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.5%[1].

Drivers of Market Growth

Rising Prevalence of Chronic Diseases

The increasing global incidence of chronic diseases such as diabetes, hypertension, cancer, and infectious diseases is a major driver. The World Health Organization (WHO) predicts that by 2025, chronic diseases will account for 73% of global deaths, and the elderly population, more susceptible to these diseases, is expected to double by 2050[1].

Technological Advancements

Modernization of drug delivery technologies, including innovative formulations and delivery systems, is enhancing patient compliance and treatment efficacy. This includes advancements in areas like precision medicine, where genomic sequencing and molecular profiling optimize treatment outcomes[3].

Government Initiatives and Reimbursement Policies

Favorable government initiatives and supportive reimbursement policies are also driving growth. These policies make drug delivery products more affordable and accessible, particularly in regions like North America, where there is high demand for these technologies[1].

Challenges in the Market

Government Pricing Pressure

One of the significant challenges is the pricing pressure imposed by governments and regulatory bodies. This limits the revenue potential for pharmaceutical companies, as they are forced to reduce prices to make medicines more affordable. This pressure is particularly intense from insurers, pharmacy benefit managers (PBMs), and public and private payers[1].

Regulatory Hurdles

The development and approval of new drug delivery technologies face regulatory hurdles, which can delay market entry and increase costs. Additionally, the risk of needlestick injuries and the high cost of advanced drug delivery devices are other challenges[1].

Investment Trends in Pharmaceutical R&D

High Costs and Risks

The average cost of bringing a new drug to market is approximately $2.6 billion, with a development timeline of 10 to 15 years. The probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved[3].

Potential Rewards

Despite these challenges, successful drug development can generate substantial revenue. Blockbuster drugs, such as AbbVie's Humira, can exceed $1 billion in annual sales, providing significant returns for investors. However, the return on investment (ROI) for pharmaceutical R&D has been declining, raising concerns about the sustainability of the current R&D model[3].

Financial Flow in the Pharmaceutical Industry

Distribution of Profits

For every $100 spent on branded prescription drugs, approximately $76 goes to manufacturers, while $24 ends up in the supply chain with insurers, wholesalers, pharmacies, and PBMs. This distribution highlights the complex and often opaque nature of the drug supply chain[2].

Impact of Pricing and Rebates

Drug manufacturers give discounts and rebates to middlemen, which can mask the true net prices of drugs. This practice results in consumers not seeing much relief from price increases, despite the slower rise in net prices for manufacturers[2].

Regional Market Dynamics

North America

North America is expected to account for the largest share of the pharmaceutical drug delivery market during the forecast period. This is due to favorable reimbursement options, growing awareness of new technologies, and the presence of many global pharmaceutical giants in the region[1].

Impact of Chronic Diseases on Drug Delivery

Diabetes and Hypertension

The growing prevalence of diabetes and hypertension is driving the demand for more efficient medication delivery methods. Drugs like Sanofi's Toujeo and Novo Nordisk's Tresiba, which offer improved glycemic control and reduced risk of hypoglycemia, are examples of this trend[3].

Cancer and Cardiovascular Diseases

The oncology market and cardiovascular disease treatments are also significant areas of focus. The rising incidence of cancer and the need for advanced treatments are pushing investment in new cancer drugs, while cardiovascular drugs continue to be a major market segment[3].

Precision Medicine and Next-Generation Sequencing

Precision medicine aims to optimize treatment efficacy by leveraging genomic sequencing and molecular profiling. Next-generation sequencing technologies have made genomic analysis faster and more affordable, enabling better treatment decisions[3].

Prescription Drug Expenditures and Projections

Growth in Spending

Overall prescription drug spending is expected to rise by 10.0% to 12.0% in 2024, with clinics and hospitals anticipating an 11.0% to 13.0% increase. This growth is driven by increased utilization, new drug approvals, and price increases[4].

Impact of Co-payments

Studies have shown that greater cost sharing through co-payments can reduce consumer spending on prescription drugs but may also lead to non-compliance and increased complications, particularly for chronic diseases like diabetes[5].

Key Takeaways

  • The global pharmaceutical drug delivery market is projected to grow significantly, driven by the rising prevalence of chronic diseases and technological advancements.
  • Government pricing pressure and regulatory hurdles are key challenges.
  • Investment in pharmaceutical R&D is high-risk but potentially highly rewarding.
  • Regional markets, especially North America, are expected to drive growth.
  • Precision medicine and next-generation sequencing are transforming treatment approaches.
  • Prescription drug expenditures are expected to continue rising, influenced by new drug approvals and pricing strategies.

Frequently Asked Questions (FAQs)

What are the primary drivers of the pharmaceutical drug delivery market?

The primary drivers include the increasing global prevalence of chronic diseases, technological advancements in drug delivery systems, and the growing geriatric population requiring more efficient medication delivery methods[1].

How does government pricing pressure affect pharmaceutical companies?

Government pricing pressure limits the revenue potential for pharmaceutical companies by imposing price caps, which are exacerbated by insurers and PBMs negotiating for reduced drug costs[1].

What role does precision medicine play in the pharmaceutical industry?

Precision medicine optimizes treatment efficacy by leveraging genomic sequencing and molecular profiling to identify predictive biomarkers, making treatments more targeted and effective[3].

How does the distribution of profits work in the pharmaceutical supply chain?

For every $100 spent on branded prescription drugs, approximately $76 goes to manufacturers, while $24 ends up in the supply chain with insurers, wholesalers, pharmacies, and PBMs[2].

What are the projections for prescription drug spending in 2024?

Overall prescription drug spending is expected to rise by 10.0% to 12.0% in 2024, with clinics and hospitals anticipating an 11.0% to 13.0% increase[4].

Cited Sources:

  1. MarketsandMarkets, "Pharmaceutical Drug Delivery Market Growth, Drivers & Opportunities"
  2. STAT, "Follow the Money to Understand How Drug Profits Flow"
  3. DrugBank Blog, "Investment Trends in Pharmaceutical Research"
  4. PubMed, "National trends in prescription drug expenditures and projections for 2024"
  5. NBER, "Effects of Co-payment on Prescription Drug Demand"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.